Reported Earlier, J&J Says Biosense Webster Submits Application To U.S. FDA Seeking Approval Of Varipulse Platform For Treatment Of Paroxysmal Atrial Fibrillation
Portfolio Pulse from Benzinga Newsdesk
Biosense Webster, a Johnson & Johnson MedTech company, has submitted the VARIPULSE™ Platform for FDA approval for treating Paroxysmal Atrial Fibrillation. Supported by the admIRE study, the platform includes a catheter, generator, and software integrated with the CARTO™ 3 System for real-time cardiac mapping. The study showed 100% acute success and 80% freedom from atrial arrhythmia recurrence at 12 months, with no reported adverse events.
March 25, 2024 | 5:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's subsidiary, Biosense Webster, has submitted the VARIPULSE™ Platform for FDA approval, showing promising results in treating Atrial Fibrillation.
The submission of the VARIPULSE™ Platform by Biosense Webster, a Johnson & Johnson company, for FDA approval is a significant step towards expanding J&J's portfolio in cardiac arrhythmia treatment. The positive results from the admIRE study, demonstrating high success rates and no adverse events, suggest a strong potential for market acceptance and future revenue growth. This development is likely to be viewed positively by investors, potentially leading to a short-term uptick in JNJ's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90